Diabetes Research Center at Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
NCT Number: NCT00607230
Type 1 diabetes is caused by an autoimmune destruction of the insulin producing cells of the pancreas. The investigators have discovered the specific autoimmune cells responsible for destroying the insulin-producing cells in an animal model of type 1 diabetes, and the means of destroying those cells.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Boston, Massachusetts, 02114, United States
The investigators are now aiming to use a similar strategy (vaccination with BCG, the vaccine used world-wide to protect against tuberculosis) in human type 1 diabetes to see if the abnormal immune cells can be depleted. This is the first step in trying to cure established type 1 diabetes.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(Type 1 diabetic subjects):
Exclusion criteria
Type 1 diabetic subjects):
Inclusion criteria
(Control Non-diabetic Subjects):
Exclusion criteria
(Control Non-diabetic Subjects):
BCG vaccination at 0 and 4 weeks
Saline vaccination at 0 and 4 weeks
Time frame: Measured weekly in first 8 weeks, then every other week for weeks 8-12
Time frame: Weekly for first 8 weeks, then every other week for weeks 8-12
Massachusetts General Hospital
Other
Determination of Dosing and Frequency of BCG Administration Necessary to Alter T-Lymphocyte Profiles in Type I Diabetics
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00807651
Autoimmune Diseases, Diabetes Mellitus
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT00378508
Autoimmune Diseases, Diabetes Mellitus
San Francisco, California, United States
View Trial DetailsNCT03880760
Autoimmune Diseases, Diabetes Mellitus
Taichung, Taiwan
View Trial DetailsNCT03272269
Autoimmune Diseases, Diabetes Mellitus
Brussels, Belgium
View Trial Details